The non-sulfonylurea secretagogues were introduced in the 1990s and enhance insulin secretion in a more glucose-dependent manner, which reduces the risk of hypoglycemia compared to sulfonylureas [98]. The gene discussed is INS; the disease is Hypoglycemia.